Consent given pursuant to sections 14 and 14A for the supply and importation of the Therapeutic Goods specified subject to conditions specified - between 20 May 2014 and 20 May 2015

Overview

The Therapeutic Goods Act 1989, enacted to regulate the supply and importation of therapeutic goods in Australia, addresses issues related to the quality, safety, and efficacy of these products. The Act provides the Therapeutic Goods Administration (TGA) with the authority to control the availability and use of therapeutic goods, ensuring they meet necessary standards. One of the key problems the Act aimed to address was the need for stringent oversight of medicines and medical devices to protect public health. This legislation was enacted by the Commonwealth Parliament and its policy objective is to safeguard the health of the Australian public by ensuring that therapeutic goods are of acceptable quality, safety, and efficacy. Recently, the delegate of the Secretary of the Department of Health granted consent for the importation and supply of oestriol products under specific conditions, reflecting the Act’s role in balancing regulatory requirements with the practicalities of medical supply.

Scope and Application

The Therapeutic Goods Act 1989 applies to therapeutic goods and their regulation, impacting a broad range of entities including pharmaceutical companies, medical device manufacturers, and health professionals. The Act governs the importation, supply, and advertising of therapeutic goods within Australia, ensuring they meet safety, quality, and efficacy standards. Its reach is national, extending to all states and territories under Commonwealth jurisdiction, with the Therapeutic Goods Administration (TGA) as the central regulatory body. Specific exclusions and exemptions may apply, particularly for research or personal use items, but these are outlined in the Therapeutic Goods Regulations. The Act's application can be further tailored through subordinate instruments, allowing for updates and refinements in response to evolving health and safety considerations. In the specific case of Aspen Pharmacare Australia Pty Ltd, the Therapeutic Goods Act 1989 facilitates the temporary consent for the importation and supply of oestriol products with non-compliant labels, provided certain conditions are met. This consent, granted under section 14A, is limited to the period from May 20, 2014, to May 20, 2015, and mandates that the existing labels indicating previous sponsor details remain unchanged while arrangements are made to redirect all correspondence to the current sponsor. This instance underscores the Act's flexibility in accommodating transitional measures while maintaining stringent oversight of therapeutic goods within Australia.

Key Provisions

The Therapeutic Goods Act 1989, as amended, contains provisions that allow for the importation and supply of certain therapeutic goods under specific conditions. In this instance, sections 14 and 14A of the Act were invoked by Aspen Pharmacare Australia Pty Ltd to seek consent for the importation and supply of oestriol (OVESTIN) in the form of 1 mg tablet blister packs and 1 mg/g cream tubes. These products, identified by their AUST R numbers 14514 and 14515 respectively, do not conform to the labelling requirements outlined in paragraph 3(2)(l) of the Therapeutic Goods Order No. 69, which pertains to the general requirements for labels for medicines. Specifically, the labels of these products still contain the contact details of the previous sponsor rather than the current sponsor, Aspen. Under the authority granted by subsection 15(1) of the Act, the delegate of the Secretary of the Department of Health has granted this consent, effective from May 20, 2014 until May 20, 2015. This consent comes with certain conditions to ensure compliance with the regulatory framework. Firstly, the labels supplied with the oestriol products must be those that currently bear the previous sponsor's contact details. Secondly, Aspen must have arrangements in place to ensure that all correspondence related to the products is redirected to the current sponsor. Additionally, the consent stipulates that no other changes should be made to the products outside of these specified conditions. The Therapeutic Goods Act imposes various obligations on parties involved in the importation and supply of therapeutic goods. For Aspen Pharmacare Australia Pty Ltd, these obligations include adhering to the conditions set by the delegate of the Secretary, such as maintaining the existing labels and ensuring proper redirection of correspondence. Compliance with these conditions is critical to avoid any regulatory repercussions. Failure to meet these obligations could potentially lead to enforcement actions, including the possibility of fines or other penalties as prescribed by the Act. It is essential that Aspen maintains accurate records and processes to demonstrate compliance with the conditions attached to the consent. In terms of potential penalties, the Therapeutic Goods Act includes provisions for both civil and criminal consequences for breaches of its requirements. For example, under section 24 of the Act, a person who contravenes a provision of the Act may be subject to fines and penalties as stipulated in the legislation. The specific penalties can vary depending on the nature and severity of the breach, but they may include significant fines for corporate entities. Additionally, under section 36, a person who is found guilty of an offence against the Act may face imprisonment. The exact penalties are determined by the courts and can be influenced by factors such as the intent behind the breach and any previous history of non-compliance.